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Introduction 
Working on this pediatric cancer research project has been influential on me academically 
and personally. As a Biology and Chemistty double major, I was given the opportunity to work 
on this research collaboration between Dr. Lori Hensley from the Biology Department and Dr. 
Marty Perry from the Chemistry Department. Working with both professors allowed me to fully 
grasp the research, from theoretical modeling to testing out our hypothesis in lab. Based on the 
major principle that structure determines function, I compared protein receptors that were 
geometrically similar to a known receptor relevant to our study, and such protein analogues were 
hypothesized to function similarly by binding to the same ligand. After analyzing the interaction 
between the protein analogue and ligand, we tested the receptors in the lab with antibodies. 
From lab, I learned a great deal of key scientific principles, such as protein-ligand interaction and 
cell growth/proliferation. Observing, applying, and connecting key concepts learned from class 
and seen in the lab helped solidify my growing scientific knowledge. Many of the skills I honed 
in research taught me how to think critically and follow through steps accurately and precisely. 
After Ouachita, I hope to pursue a medical degree and become a pediatrician. Studying 
Ewing's sarcoma opened my eyes to the great need for proper treatment for children in critical 
care. There seems to be an unfortunate difference in research funding between the adult and 
pediatric demographics. I hope to continue research in a clinical setting where I can also care for 
children in the intensive care units and hematology-oncology departments. Lastly, I have learned 
the importance of teamwork. The collaboration and help from Dr. Hensley, Dr. Perry, and Mrs. 
Eubanks made this research possible, intriguing, and exciting. Nearing the end of my 
undergraduate career at Ouachita, I would whole-heartedly recommend that all freshmen 
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seriously consider research. Through research, one will gain a more comprehensive education, a 
sparked interest in certain fields of study, and the value of teamwork. 
Abstract 
Ewing's Sarcoma (ES) is a malignant cancer characterized by the formation of tumors in 
bones or soft tissues of primarily children and young adults. 1 With the tendency for local 
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recurrence and metastasis, ES is an aggressive cancer. The treatment is intensive and often 
yields poor long-term results. A cannabinoid derived compound, ajulemic acid (AJA), has shown 
strong cytotoxic effects on ES cell lines. The synthetic compound is unlike its cannabinoid 
counterpart tetrahydrocannabinol by lacking psychotropic effects . To investigate the possibility 
of utilizing AJA as a chemotherapeutic drug, the biochemical mechanism behind the cytotoxic 
effects of AJA needs further research. A proposed mechanism includes the binding of AJA to 
nuclear receptors in ES cells such as peroxisome proliferator-activated receptor (PPAR-y). While 
past studies have provided great evidence for AJA binding to PPAR-y, data from western blot 
analysis indicate the absence ofPPAR-y receptors in ES cells. Computational analysis was 
employed to find 3D structural analogs ofPPAR-y by using SMAP software program to generate 
a list of such analogs with PPAR-y as the template. 2 One of the receptors most similar to PPAR-
y was vitamin D3 receptor (VD3R). Next, Surflex Dock, from Tripos Inc. Sybyl-X 1.3 program, 
measured how well AJA docked with VD3R by calculating total scores, crash score, C-scores, 
and global C-scores.3•4 Total scores greater than 7, and both C-scores and global C-scores of 4-5 
indicated a good fit. The next step in determining, ifVD3R could be an important receptor 
through which AJA is working, is to investigate its expression in ES cells and effects on cell 
viability which appropriate antagonists are used. 
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Background 
Ewing's sarcoma (ES), a member of the Ewing's sarcoma family of tumors, is the second 
most prevalent pediatric bone cancer. 1 ES is an aggressive cancer that affects primarily 
caucasians, and more males than females. The median age ofES patients is 15 years old. 1 In 
95% ofES cases, the genetic mutation is a translocation of either chromosomes 11 and 22 or 
chromosomes 21 and 22. 5 There is no current research to provide evidence that ES is 
inheritable. Common histologic features of this soft tissue sarcoma are small, spherical, blue 
cells with possible origins from neural crest cells or mesenchymaJ.S Tumor masses are mostly 
found in the lower extremity ( 41 %), pelvis (26%), chest wall (16%), and upper extremity (9%). 1 
Prior to chemotherapy, the long-term survival rate was 10%. Modern multi-disciplinary 
treatments have increased the prognosis such that patients with localized tumors have a 75% 
survival rate. Despite all the medical advancements, almost half of the treatments given are 
either ineffective or unnecessary. 6 The prevailing treatment could result in short-term or long-
term toxicities and greatly compromise the patient's immune system. Surgeries are also a 
treatment option, but may require amputation. 7 Furthermore, prognosis for metastatic and 
recurrent tumors remain poor. Metastases occur in 25% of the patients, with the most common 
sites found in the lungs (50%), bone (25%) and bone marrow (20%).8 Once the cancer has 
metastasized, the overall survival is 30%. 9 Recurrent tumors typically occur within two years of 
diagnosis, resulting in an extremely low overall survival rate of 7%. 10 
Growing evidence supported by recent studies suggests that cannabinoids, specifically 
ajulemic acid (AJA), can be a viable treatment for ES. 11 There are three major types of 
cannabinoids- herbal, endogenous, and synthetic. Herbal cannabinoids, such as 
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tetrahydrocannabinol (THC), are extracted from the marijuana plant Cannabis sativa L. and are 
known for producing psychotropic effects. Endogenous cannabinoids, e.g. anandamide, are 
naturally produced in humans and bind to cannabinoid receptors CBl and/or CB2. 11 Ajulemic 
acid is a synthetic cannabinoid that structurally similar to THC. Cannabinoids in general have 
displayed anticancer properties in many current studies. 12 AJA, in particular, is promising 
treatment because it effectively kills tumor cells and does not show any psychotrophic effects 
when administ~red. 1 In Dr. Hensley's lab, substantial data have revealed that AJA effectively 
induces apoptosis (i.e. programmed cell death) in ES cells. However, her results indicate that the 
typical cannabinoid receptors, CB 1 and CB2, are not the targeted receptors for AJA. 10 The exact 
mechanism behind the cytotoxic effects of AJA remains a mystery. 
Ambrosio et al. revealed that AJA binds exceptionally well to the ligand binding domain 
of the human peroxisome proliferator-activated receptor-y (PPAR-y). PPAR-y is a member of the 
nuclear receptor (NR) superfamily of ligand-activated transcription factors that are involved in a 
variety of cellular processes such as adipose differentiation and inflammatory and immune 
response. Since AJA binds well to PPAR-y and is associated with several important cellular 
processes, it is plausible that PPAR-y is a major component to the cytotoxic mechanism. 
However, western-blots revealed that ES cells do not express PPAR-y. 13 
Despite the negative results, the data was an impetus for investigating structurally similar 
PPAR-y receptors using computational software. Studies have supported the idea that similar 
three-dimensional (3D) shapes, rather than identical amino acid sequences, mainly determine 
similar functions between proteins. Accordingly, a Functional Site Analysis Resources program 
called SMAP was utilized to cipher through the human proteome in order to find analogous 3D 
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structures using PPAR-y as the template. 13 The SMAP software generates such analogs based on 
scores as measured by overall protein structure, binding sites, and chains comparison. According 
to the protocol, p-values less than lxl0-4 and a Tanimotto coefficient greater than 0.5 were the 
two favorable scores employed to find proteins with a similar ligand binding domain (LBD) to 
PPAR-y. 3 Of the four chains, PPAR-y C-Chain provided a list of nuclear receptors with the best 
scores. This NR list included vitamin D3 receptors (VD3R). 
Once a promising receptor was identified, the interaction and binding of the AJA ligand 
to the receptor was calculated using the Surflex Dock and protein flexibility of Sybyl-X 1.3. The 
Surflex Dock and protein flexibility measured how well AJA docked with VD3R by generating 
ligand based protomols and calculating the following scores, listed in order of hierarchy- total 
scores, C-scores, and global C-scores. Ligand based protomols are computer generated maps of 
of possible interaction with ligands in the proteins LBD, i.e. the region specified as the active site 
of the protein. Numerous conformations of the ligand were performed in an attempt to include as 
many interactions between the ligand and residues in the LBD. The total score is a numerical 
value equal to the ligand-protein interaction expression as -log(Kd). The C-score is the 
comprehensive score. Total scores greater than 7 and both C-scores and global C-scores of 4-5 
indicated a good fit. 
VD3R, also known as calcitriol receptors, could be the receptor to which AJA binds in ES 
cells. Calcitriol is a lipid soluble steroid that regulates several major cellular functions such as 
"cell growth, differentiation, antiproliferation, apoptosis, and calcium/phosphate homeostasis." 14 
This steroidal nuclear receptor is a ligand-activated transcriptional regulator, just like PPAR-y. 
In addition, VD3R is expressed in a variety of cancers, e.g. pancreatic, lung, breast, and even 
osteosarcomas. 13 Therefore, VD3R is a promising receptor for AJA in ES cells. 
Purpose 
(1) DockAJA to VD3R generated from SMAP list using Sybyl-X 1.3 programs Surflex 
Dock and protein flexibility to measure the induced fit. (2) Western blot to determine the 
presence of pertinent receptors in ES cell lines. (3) Perform a MTT assay to calculate the 
cytotoxic effect of AJA on cells containing VD3R with good docking scores and appropriate 
antagonists. 
Experimental Design/Procedure: Computational Analysis 
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A list of 3D structural analogs to PPAR-y was generated and imported into a Microsoft 
Excel spreadsheet. Nuclear receptors with the best scores were identified using RCSB Protein 
Data Bank (PDB). VD3R that were not human proteins were ignored. Receptors with ligands 
already bound to the LBD were preferentially analyzed. Next, the proteins were individually 
prepared, Surflex Docked, and measured for protein flexibility using Tripos Inc. Sybyl-X 1.3 
program. The preparation involved adding hydrogen atoms to the protein, Gasteiger-Huckel 
charges, and were minimized with 10,000 iterations. At the end of the minimization, the protein 
were named with their respective "PDB ID _MIN." After minimization, everything was deleted 
on the Sybyl screen since nothing needed to be opened to run a Surflex Dock. The Surflex Dock 
box was opened for protomol generation. The prepared protein was loaded and the protomol was 
created using the ligand route. The ligand naturally bound to VD3R was extracted by selecting 
the "Extract Ligand Substructures." After highlighting the ligand and applying it, the browser 
returned to the main Surflex Dock box. Under Protomol Generation, the "Ligand" option was 
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selected. The Mol2 File was changed to Mol Area that contained the newly extracted ligand. 
Then, "Generate" was selected and the protomol formed (Figure 1 ). Next, AJA was loaded by 
changing from SLN file to Mol2 file. The Surflex Dock options were modified by: imputing 3 
Additional Starting Conformation per Molecule, 12 Angstroms to Expand Search Grid, 200 Max 
Conformations per Fragment, 200 Max Number of Roatable Bonds per molecule, 200 Maximum 
Number of Poses per Ligand, and 0.05 Minimum RMSD Between Final Poses. Ajobname was 
created and the "OK" option was selected. To determine protein flexibility, the following items 
were selected "Hydrogen, Heavy Atoms, and Fast Protein Flex (Less Thorough Search)" and 
everything else was kept the same (Figure 2). Once the "Dock" was completed, the scores were 
analyzed in the Results Browser. The protein was loaded by selecting "View." The total score, 
crash score, C-score, global C-score, and polar score were all recorded. This process was 
repeated until sufficient numbers ofVD3Rs were analyzed. 
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Figure 1: Protomol Generation 
Uploaded 2HB7 VD3R from PDB and used Tripos Inc. Sybyl-X 1.3 software program Surflex 
Dock. The grey region represents the protomol, the region specified as the active site of the 
protein. 
Figure 2: Protein Flexibility 
Prepare ..• 1 
Multi - Channel 
Surface 
O.SO Bloat(/oJ 0 
·= == <) 
Uploaded 2HAR VD3R from PDB and used the Protein Flexibility program from Surflex Dock. 
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Results: Computational Analysis 
PDB Codt> Tota]1 Crash2 C-scorel GC-scort>" Pola,.S 
1IE9 7.1029 -6.6530 3 3 1.0856 
2HB7 8.2514 -3.0549 3 3 0.0000 
2BA."J\II 7.7245 -4.1694 3 3 0.0006 
2HAR 9.3630 -3.8722 5 5 0.0082 
2HAS 8.1635 -3.1904 3 3 0.0000 
3AUR 6.3625 -4.6141 2 2 1.1360 
3AZ1 4.3390 -8.2508 3 3 1.0294 
3AZ3 7.3469 -5.4011 3 3 0.0000 
2HB8 7.9446 -5.1736 3 3 1.1572 
lDBl 7.5854 -5.7765 3 3 1.2919 
30GT 3.8948 -8.2414 4 4 0.0001 
3TKC 5.2539 -7.6192 3 3 2.3025 
2SOZ 6.5384 -5.6310 4 4 0.0001 
1819 5.6125 -5.0560 3 3 0.0006 
3AZ2 8.0990 -3.7553 4 4 0.0000 
1pKd= -log(Kd) is a measurement of ligand-protein interaction 
2Crash score io; a measurement of the unwanted penetration the ligand has into the protein space. If 
the crash score is r-educed from -2.00 to -1.00, the total score will increase by 1. 
3C-scm·e is comprehensin score: 1 is worst, 3 is anrage, and 5 is the best 
4Global C-score is essentially the same as C-score 
5Polar score is a measurement of how much of the total score is due to polar interactions 
Table 1: Surflex Dock Results with Strong Scores 
The relatively high total scores for different uploaded VD3Rs suggest that AJA would bind well at 
the LBD of the nuclear receptor, despite the unfavorable crash scores. 2HAR had the best scores 
overall, with the highest total score, C-score, and GC-score. 30 GT had the lowest total score, but 
its C-score and GC-score were 4. 
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Conclusion: Computation Analysis 
Several VD3Rs from PDB were uploaded into Sybyl-X 1.3 to be Surflex Docked with 
AJA. A set of scores was compiled to measure how well AJA would bind to VD3R. In order of 
importance, the scores recorded were highest total score, low crash score, C-score, GC-score, 
and polar score. Total scores that were 7 and above indicate good ligand-protein interaction. Ten 
VD3RS from the PDB had total scores greater than 7. VD3R from PDB with the best overall 
scores were 2HB7, 2HAR, 2HAS, 3AZ3, 2HB8, 3CS6, and 3AZ3 respectively (see Table 1). 
Low crash scores, calculated by the absolute value of the number given from Surflex Dock, were 
not attained. The C-scores and GC-scores were fairly average. VD3Rs with higher total scores 
seemed to have smaller polar scores. Overall, the scores suggest AJA would bind well to VD3R 
in vivo. If so, VD3R could be the receptor that mediates the signal for apoptosis in ES. 
Experimental Method: Western Blot for VD3R Expression 
Two western blot sample sets were conducted, one with blocking peptide and one without 
the blocking peptide. The blocking peptide functions as a binding specificity control because 
they bind to the VD3R antibodies, rendering the antibodies unable to bind to the epitope. One 
set contained 8 total samples, half with untreated cells and the other half with cells treated for 24 
hr with 32 J.!M AJA. Samples 1-3 of untreated cells contained 5 J.!L lysate, 20.2 J.!L phosphate 
buffered saline (PBS), 9 J.!L lithium dodecyl sulfate (LDS), and 1.8 J.!L dithiothreitol (DTT). 
Samples 4-6 of 32 J.!M AJA had the same volumes and concentrations as samples 1-3. Sample 7 
contained untreated cells with 10 J.!L lysate, 15.2 J.!L PBS, 9 J.!L LDS, and 1.8 J.!L DTT. Sample 8 
contained cells treated with 32 J.!M AJA mixed with 10 J.!L lysate, 15.2 J.!L PBS, 9 J.!L LDS, and 
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1.8 f.lL DTT. The electrophoresis ran at 150 V until the blue was at the bottom of the gel. The 
transfer ran at 200 rnA for 1.5 hr. Then, 15 f.lL of 1° antibody (Santa Cruz Biotechnology VD3R 
sc-1 008) was dispensed and incubated with the gels overnight in the fridge with 3 mL of 
blocking solution. The peptide neutralization protocol involved 75 f.lL blocking peptide, 15 f.lL 
VD3R antibody, and 410 f.lL PBS. Next in sequential order, the gel was washed, incubated in the 
fridge for 1 hr with the 2° VD3R antibody, washed again, and developed. For the second 
western blot gel, similar protocol was followed excluding the blocking peptide. The molecular 
weight ofVD3R is 51 kDa, thus strong bands should appear in the western blot without the 
blocking peptide in the 51 kDa band region. However, for the western blot with the blocking 
peptide, the bands should be absent in that region. 
Results: Western Blot 
Figure 3: Western Blot #1 
TC71-PM4-GR AJA VDR Antibody Without Blocking Peptide 
Lane1 Lane2 Lane3 Lane4 Lanes Lane6 .._7 ~8 
SlK 
51K 
Figure 4: Western Blot #2 
TC71-PM4-GR AJA VDR Antibody with Blocking Peptide 
Lane 1 Lane 2 Lane 3 Lane 4 Lane 5 Lane 6 Lane 7 Lane 8 
Uot 1 Uot 1 Unt 1 3211! l 321L~ 32pM 1.\Tar l.U21L\f 
Figures 3 and 4: Western Blots 
13 
The presence ofbands at 51 kDa in Figure 3 reveal the presence ofVD3R in ES cells. The 
faint bands in Figure 4, compared to the dark bands in the western blot in Figure 3, indicate that 
the blocking peptide prevented (for the most part) the antibody from binding to the epitope and 
thus, helped specify the staining pattern of the VD3R antibody. 
Conclusion: Western Blot 
The presence of bands at 51 kDa in Figure 3 confirm the presence ofVD3R in ES cells. 
The bands appear because the VD3R antibodies bind to the epitope on the protein. The receptor 
was present in both the untreated and treated cells with 32 f..LM AJA. In both western blots, Lanes 
1-4 with more concentrated proteins displayed darker bands than the less concentrated Lanes 5-8. 
The second western blot with the blocking peptide in Figure 4 had noticeably faint bands near 
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the 51 kDa region. Ideally, nothing should appear in the 51 kDa region. The blocking peptides 
bind to the VD3R antibody and prevents the antibody from binding to the epitope. The presence 
of the faint bands is most likely due to the long, overnight incubation of the 1 o antibody. The 
incubation is usually a couple hours and can last up to 24 hours. With a longer incubation time, 
the antibodies had the opportunity to bind the epitope despite the presence of the blocking 
peptides. Nonetheless, the strong bands present in the 51 k:Da region in the first western blot ' 
confirm the presence ofVD3R in ES cells. 
Experimental Design/Procedure: MTT assay 
The final step of the research was to conduct a MIT assay with the VD3R antibody on 
ES cell lines TC71-PM4-GR. This colormetric assay is a measurement of percent cell viability. 
The mitochondrial succinate dehydrogenase reduces soluble MIT (a yellow colored tetrazolium 
salt) to an insoluble, blue-purple formazan. The color intensity is measured via 
spectrophotometer. Living cells are actively respiring, thus the color intensity is directly 
proportional to the number of viable cells. IfVD3R is the receptor that mediates apoptosis in ES 
cells treated with AJA, then high percent cell viability should be expected from both VD3R 
antibody alone and antibody plus AJA treated cells because the antibody should block the ability 
of AJA to bind. A 24 well plate contained the following: untreated cells (wells 1-3); 16 ~ AJA 
(wells 4-6); 1:50 VD3R antibody (wells 7-9); 1:500 VD3R antibody (wells 10-12); 1:50 VD3R 
plus 16 j!M AJA (wells 13-15); and 1:500 VD3R antibody plus 16 j!M AJA (wells 16-18). The 
wells with AJA were treated with the drug after 30 min of adding the appropriate media and 
VD3R antibody concentrations. 
Results: MTT Assay 
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"* Figure 5: Cell Viability 
The wells containing the antibody and AJA had unexpectedly low percent cell viability. Since 
1:50 VD3R, compared to 1:500 VD3R, greatly reduces percent cell viability, there may be a 
correlation between dosage of antibody and magnitude of cell death. 
~ RILEY-HICKINGBOTHAM LIBRARY 0 
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Conclusion: MTT Assay 
The pilot assay seems to suggest that the binding of the VD3R antibody to the nuclear 
receptor acts as a partial agonist and is further exacerbated when AJA is present. The wells with 
the untreated cells had the expected high percent cell viability. Similarly, the wells treated with 
AJA alone had low percent cell viability. However, the VD3R antibody was hoped to act as an 
antagonist and block the AJA from binding to the VD3R. Accordingly, a high percent cell 
viability was expected. Yet the percent cell viability was low for the VD3R antibody treatment 
and antibody plus AJA. One interesting observation was that since 1:50 VD3R, compared to the 
1:500 VD3R, greatly reduced percent cell viability, there may be a correlation between dosage of 
antibody and magnitude of cell death (Figure 5). While this pilot assay does not definitively 
affirm VD3R as the receptor to which AJA binds and signals apoptosis in ES it does suggest the 
VD3R can mediate cell death in ES cells, but that the antibody may activate, not block, the 
receptor. More controlled assays are necessary, and a true VD3R antagonist is needed. 
Further Directions 
As mentioned previously, another controlled MTT assay is necessary. The second assay 
should include a positive control with vitamin D3 and a negative control with a known 
antagonist. With a limited amount of time and resources, the pilot assay had to be accomplished 
with an antibody instead of a known antagonist. Interestingly, all nuclear receptors [PPAR-y, 
retinoic acid receptor alpha (RAR-a), and VD3R] tested thus far as possible receptors for AJA 
are heterodimers of another receptor, retinoic X receptor (RXR). In addition to testing VD3R in 
future assays, RXR should be tested with VD3R. IfVD3R is not the main mediator in the 
I 
cytotoxic pathway, AJA-RXR interaction should be analyzed similarly using SMAP, Surflex 
Dock, and Protein Flexibility. Another set of western blots would be appropriate to confirm the 
presence of the receptor. Along with the computational analysis and western blots, a more 
controlled MTT assay can be conducted for future experiments. 
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